NCT05629299

Brief Summary

Given the current emerging epidemic of the MonkeyPox Virus (MPXV) and its route of transmission, the main objective of this pilot study is to characterize the presence of the MPXV in the semen of patients in the acute phase of infection and following this infection.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Nov 2022

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2022

Completed
14 days until next milestone

First Submitted

Initial submission to the registry

November 15, 2022

Completed
14 days until next milestone

First Posted

Study publicly available on registry

November 29, 2022

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2024

Completed
Last Updated

November 29, 2022

Status Verified

November 1, 2022

Enrollment Period

2 years

First QC Date

November 15, 2022

Last Update Submit

November 28, 2022

Conditions

Keywords

Monkeypox Virussementesticleacute phase and follow-up

Outcome Measures

Primary Outcomes (1)

  • MPXV genomic DNA

    presence of MPXV DNA in the semen and others body fluids of infected patients in the acute phase and during the follow-up.

    Day 0

Study Arms (1)

Monkey Pox infection

OTHER

Men will give semen, saliva, skin, urine and blood specimens

Biological: Samples

Interventions

SamplesBIOLOGICAL

Men will give semen, saliva, skin, urine and blood specimens

Monkey Pox infection

Eligibility Criteria

Age18 Years - 50 Years
Sexmale(Gender-based eligibility)
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • in the acute phase of MPXV infection and whose PCR reveals the viral genome in a skin sample or in any other sample.
  • able to travel to the laboratory for the samples
  • who gave his free and informed consent and having signed the consent
  • Patient affiliated to a social security scheme or equivalent

You may not qualify if:

  • Patient who has previously consulted for male infertility or who has previously performed an abnormal semen test (WHO standard)
  • Patient with ejaculation disorder or unable to collect semen or with abnormal semen volume (\<1.5 mL).
  • Patient who presents serious clinical signs that do not allow him to travel to the investigation center.
  • Patient under a protection regime (including guardianship, curatorship or safeguard of justice)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU Toulouse

Toulouse, France

Location

MeSH Terms

Conditions

Mpox, Monkeypox

Interventions

Sampling Studies

Condition Hierarchy (Ancestors)

Poxviridae InfectionsDNA Virus InfectionsVirus DiseasesInfectionsPrimate DiseasesAnimal DiseasesRodent Diseases

Intervention Hierarchy (Ancestors)

Epidemiologic Study CharacteristicsEpidemiologic MethodsInvestigative TechniquesHealth Care Evaluation MechanismsQuality of Health CareHealth Care Quality, Access, and EvaluationPublic HealthEnvironment and Public Health

Study Officials

  • Manon CARLES, MD

    University Hospital, Toulouse

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 15, 2022

First Posted

November 29, 2022

Study Start

November 1, 2022

Primary Completion

November 1, 2024

Study Completion

November 1, 2024

Last Updated

November 29, 2022

Record last verified: 2022-11

Data Sharing

IPD Sharing
Will not share

Locations